Vertex Pharmaceuticals Price Target, Predictions & Analyst Ratings

-0.51 (-0.27 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume3.52 million shs
Average Volume2.05 million shs
Market Capitalization$48.63 billion
P/E Ratio17.89
Dividend YieldN/A

Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
25 Wall Street analysts have issued ratings and price targets for Vertex Pharmaceuticals in the last 12 months. Their average twelve-month price target is $275.86, predicting that the stock has a possible upside of 46.85%. The high price target for VRTX is $340.00 and the low price target for VRTX is $200.00. There are currently 5 hold ratings and 20 buy ratings for the stock, resulting in a consensus rating of "Buy."
TypeToday30 Days Ago90 Days Ago180 Days Ago
VRTX Consensus Rating: BuyBuyBuyBuy
VRTX Consensus Rating Score: 2.802.852.882.81
VRTX Analyst Ratings: 0 Sell Rating(s)
5 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
21 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
23 Buy Rating(s)
1 Strong Buy Rating(s)
VRTX Consensus Price Target: $275.86$292.00$293.13$290.83
VRTX Price Target Upside: 46.85% upside19.24% upside18.51% upside19.69% upside

Vertex Pharmaceuticals (NASDAQ:VRTX) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Vertex Pharmaceuticals (NASDAQ:VRTX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/14/2021TruistBoost Price TargetBuy$305.00 ➝ $331.00Low
6/14/2021Piper SandlerLower Price TargetOverweight$347.00 ➝ $261.00Low
6/14/2021Truist SecuritiesBoost Price TargetBuy$305.00 ➝ $331.00Low
6/14/2021SVB LeerinkLower Price TargetReduce ➝ Market Perform$250.00 ➝ $200.00Low
6/13/2021Evercore ISIReiterated RatingBuyLow
6/11/2021Stifel NicolausLower Price TargetBuy$277.00 ➝ $244.00High
6/11/2021The Goldman Sachs GroupLower Price TargetBuy$358.00 ➝ $307.00High
6/11/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price TargetBuy$325.00 ➝ $285.00High
6/11/2021BarclaysLower Price TargetOverweight$302.00 ➝ $285.00High
6/11/2021Cantor FitzgeraldLower Price TargetOverweight$285.00 ➝ $281.00High
6/11/2021Morgan StanleyLower Price TargetEqual Weight$254.00 ➝ $205.00High
6/11/2021Robert W. BairdLower Price TargetOutperform$252.00 ➝ $240.00High
6/11/2021Royal Bank of CanadaLower Price TargetPositive ➝ Outperform$262.00 ➝ $242.00High
6/11/2021Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$210.00High
2/2/2021BMO Capital MarketsLower Price TargetOutperform$302.00 ➝ $284.00Low
2/2/2021Credit Suisse GroupLower Price TargetOutperform$285.00 ➝ $280.00Low
2/2/2021HC WainwrightLower Price TargetBuy$315.00 ➝ $275.00Low
12/11/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
11/20/2020Sanford C. BernsteinInitiated CoverageOutperform$275.00Low
10/28/2020UBS GroupInitiated CoverageBuy$287.00Low
10/26/2020Needham & Company LLCReiterated RatingHoldMedium
9/18/2020Maxim GroupReiterated RatingHoldHigh
7/16/2020CowenBoost Price TargetOutperform$265.00 ➝ $300.00Low
7/14/2020Jefferies Financial GroupBoost Price TargetBuy$295.00 ➝ $340.00High
6/24/2020SunTrust BanksBoost Price TargetBuy$285.00 ➝ $330.00High
5/15/2020ArgusBoost Price TargetBuy$270.00 ➝ $320.00High
4/30/2020CfraBoost Price TargetBuy$286.00 ➝ $297.00Low
4/30/2020GuggenheimBoost Price TargetBuy$266.00 ➝ $290.00High
4/30/2020OppenheimerBoost Price TargetOutperform$265.00 ➝ $305.00High
4/30/2020JMP SecuritiesBoost Price TargetMarket Outperform$255.00 ➝ $285.00High
3/12/2020Wolfe ResearchInitiated CoverageOutperform$282.00High
1/31/2020Bank of AmericaReiterated RatingBuy$250.00 ➝ $295.00High
1/6/2020Piper Jaffray CompaniesBoost Price TargetOverweight$247.00 ➝ $284.00N/A
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
3/26/2019William BlairUpgradeMarket Perform ➝ Outperform$183.85Medium
(Data available from 6/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 6/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.